Sign inJoin waitlistJoin the waitlist

Serge Jabbour

Director, Division of Endocrinology, Diabetes & Metabolic Diseases · SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY

Credentials: · · · · ·

History

SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY
Present

Endocrinology, Diabetes, and Metabolism
Thomas Jefferson University Hospital
1999–2001
Hotel-Dieu de France Hospital
1996–1999
Cooper Hospital-University Medical Center
1993–1996
ST JOSEPH'S UNIV, FAC OF MED, BEIRUT, LEBANON
1989–1993

Research

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial
JAMA · 2017 · 388 citations
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy…
The Lancet Diabetes & Endocrinology · 2016 · Last of 7 authors · 338 citations
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study
Diabetes Care · 2014 · First of 5 authors · Corresponding · 238 citations

Jeffrey Miller
8 papers
JF
Juan Frias
8 papers
AA
Azazuddin Ahmed
5 papers
CI
Charles Intenzo
5 papers
DC
David Capuzzi
5 papers
BG
Barry Goldstein
4 papers
Jeffrey Joseph
3 papers
Intekhab Ahmed
2 papers
Jaya Mehta
2 papers · 1 as a resident
JR
Julio Rosenstock
2 papers
Ralph DeFronzo
2 papers
SK
Sung Kim
2 papers

Grants

3/22 DPPOS Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) – Clinical Center
National Institute of Diabetes and Digestive and Kidney Diseases · U01
Contact PI · $918.7K · Thomas Jefferson University
1994–2014

Clinical trials

Dapagliflozin DPPIV Inhibitor add-on Study
Principal investigator · Completed · Phase 3
AstraZeneca
2009–2011
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Site PI · Recruiting · Phase 2
Zucara Therapeutics Inc.
2023–2027